{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:07:18Z","timestamp":1784034438388,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072859"],"award-info":[{"award-number":["82072859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102010292"],"award-info":[{"award-number":["202102010292"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515220127"],"award-info":[{"award-number":["2022A1515220127"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Zinc finger SWIM-type containing 4 (ZSWIM4) induces drug resistance in breast cancer cells. However, its role in epithelial ovarian cancer (EOC) remains unknown. In this study, we aimed to investigate the clinical significance of ZSWIM4 expression in EOC and develop new clinical therapeutic strategies for EOC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ZSWIM4 expression in control and EOC tumor tissues was examined using immunohistochemistry. Lentiviral transduction, Cell Counting Kit-8 assay, tumorsphere formation assay, flow cytometry, western blotting, and animal xenograft model were used to assess the role of ZSWIM4 in chemotherapy. Cleavage Under Targets and Tagmentation (CUT&amp;Tag) assays, chromatin immunoprecipitation assays, and luciferase reporter assays were used to confirm FOXK1-mediated upregulation of ZSWIM4 expression. The mechanism by which ZSWIM4 inhibition improves chemosensitivity was evaluated using RNA-sequencing. A ZSWIM4-targeting inhibitor was explored by virtual screening and surface plasmon resonance analysis. Patient-derived organoid (PDO) models were constructed from EOC tumor tissues with ZSWIM4 expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ZSWIM4 was overexpressed in EOC tumor tissues and impaired patient prognoses. Its expression correlated positively with EOC recurrence. ZSWIM4 expression was upregulated following carboplatin treatment, which, in turn, contributed to chemoresistance. Silencing ZSWIM4 expression sensitized EOC cells to carboplatin treatment in vitro and in vivo. FOXK1 could bind to the GTAAACA sequence of the <jats:italic>ZSWIM4<\/jats:italic> promoter region to upregulate <jats:italic>ZSWIM4<\/jats:italic> transcriptional activity and FOXK1 expression increased following carboplatin treatment, leading to an increase in ZSWIM4 expression. Mechanistically, ZSWIM4 knockdown downregulated the expression of several rate-limiting enzymes involved in glycine synthesis, causing a decrease in intracellular glycine levels, thus enhancing intracellular reactive oxygen species production induced by carboplatin treatment. Compound IPN60090 directly bound to ZSWIM4 protein and exerted a significant chemosensitizing effect in both EOC cells and PDO models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ZSWIM4 inhibition enhanced EOC cell chemosensitivity by ameliorating intracellular glycine metabolism reprogramming, thus providing a new potential therapeutic strategy for EOC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-024-04980-8","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:03:23Z","timestamp":1708517003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis"],"prefix":"10.1186","volume":"22","author":[{"given":"Kunxiang","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinger","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-1306","authenticated-orcid":false,"given":"Kun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"4980_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371: m3773. https:\/\/doi.org\/10.1136\/bmj.m3773.","journal-title":"BMJ"},{"key":"4980_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin"},{"key":"4980_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12032-023-01976-0","volume":"40","author":"N Singh","year":"2023","unstructured":"Singh N, Kumar A. Insights into ovarian cancer: Chemo-diversity, dose depended toxicities and survival responses. Med Oncol. 2023;40:111. https:\/\/doi.org\/10.1007\/s12032-023-01976-0.","journal-title":"Med Oncol"},{"key":"4980_CR4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353. https:\/\/doi.org\/10.1016\/0140-6736(18)32552-2.","journal-title":"Lancet"},{"key":"4980_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun. 2019;10:1295. https:\/\/doi.org\/10.1038\/s41467-019-09312-9.","journal-title":"Nat Commun"},{"key":"4980_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole\u2013genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489\u201394. https:\/\/doi.org\/10.1038\/nature14410.","journal-title":"Nature"},{"key":"4980_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116\u201320. https:\/\/doi.org\/10.1038\/nature06633.","journal-title":"Nature"},{"key":"4980_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/s0968-0004(02)02140-0","volume":"27","author":"KS Makarova","year":"2002","unstructured":"Makarova KS, Aravind L, Koonin EV. SWIM, a novel Zn-chelating domain present in bacteria, archaea and eukaryotes. Trends Biochem Sci. 2002;27:384\u20136. https:\/\/doi.org\/10.1016\/s0968-0004(02)02140-0.","journal-title":"Trends Biochem Sci"},{"key":"4980_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1042\/20200031","volume":"134","author":"HD Li","year":"2020","unstructured":"Li HD, Chen X, Xu JJ, Du XS, Yang Y, Li JJ, et al. DNMT3b-mediated methylation of ZSWIM3 enhances inflammation in alcohol-induced liver injury via regulating TRAF2-mediated NF-\u03baB pathway. Clin Sci. 2020;134:1935\u201356. https:\/\/doi.org\/10.1042\/20200031.","journal-title":"Clin Sci"},{"key":"4980_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc9359","author":"CY Shi","year":"2020","unstructured":"Shi CY, Kingston ER, Kleaveland B, Lin DH, Stubna MW, Bartel DP. The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation. Science. 2020. https:\/\/doi.org\/10.1126\/science.abc9359.","journal-title":"Science"},{"key":"4980_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc9546","author":"J Han","year":"2020","unstructured":"Han J, Lavigne CA, Jones BT, Zhang H, Gillett F, Mendell JT. A ubiquitin ligase mediates target-directed microRNA decay independently of tailing and trimming. Science. 2020. https:\/\/doi.org\/10.1126\/science.abc9546.","journal-title":"Science"},{"key":"4980_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12920-021-00905-2","volume":"14","author":"J Ma","year":"2021","unstructured":"Ma J, Wang P, Huang L, Qiao J, Li J. Bioinformatic analysis reveals an exosomal miRNA-mRNA network in colorectal cancer. BMC Med Genomics. 2021;14:60. https:\/\/doi.org\/10.1186\/s12920-021-00905-2.","journal-title":"BMC Med Genomics"},{"key":"4980_CR13","doi-asserted-by":"publisher","first-page":"15410","DOI":"10.1038\/s41598-021-94514-9","volume":"11","author":"R Vishnubalaji","year":"2021","unstructured":"Vishnubalaji R, Alajez NM. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-\u03b2 signaling. Sci Rep. 2021;11:15410. https:\/\/doi.org\/10.1038\/s41598-021-94514-9.","journal-title":"Sci Rep"},{"key":"4980_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119696","volume":"279","author":"K Gong","year":"2021","unstructured":"Gong K, Song K, Zhu Z, Xiang Q, Wang K, Shi J. SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer. Life Sci. 2021;279: 119696. https:\/\/doi.org\/10.1016\/j.lfs.2021.119696.","journal-title":"Life Sci"},{"key":"4980_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73:377\u201392. https:\/\/doi.org\/10.1007\/s00018-015-2070-4.","journal-title":"Cell Mol Life Sci"},{"key":"4980_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, Deberardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"key":"4980_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12967-015-0511-3","volume":"13","author":"DO Bauerschlag","year":"2015","unstructured":"Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, et al. Fatty acid synthase overexpression: Target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med. 2015;13:146. https:\/\/doi.org\/10.1186\/s12967-015-0511-3.","journal-title":"J Transl Med"},{"key":"4980_CR18","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1007\/s00018-021-03818-6","volume":"78","author":"P Prasad","year":"2021","unstructured":"Prasad P, Ghosh S, Roy SS. Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation. Cell Mol Life Sci. 2021;78:4821\u201345. https:\/\/doi.org\/10.1007\/s00018-021-03818-6.","journal-title":"Cell Mol Life Sci"},{"key":"4980_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.7150\/thno.8502","volume":"4","author":"X Chen","year":"2014","unstructured":"Chen X, Wei S, Ma Y, Lu J, Niu G, Xue Y, et al. Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. Theranostics. 2014;4:1164\u201375. https:\/\/doi.org\/10.7150\/thno.8502.","journal-title":"Theranostics"},{"key":"4980_CR20","doi-asserted-by":"publisher","first-page":"1063305","DOI":"10.3389\/fonc.2022.1063305","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu S, Wang ZM, Lv DM, Zhao YX. Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: a systematic review. Front Oncol. 2022;12:1063305. https:\/\/doi.org\/10.3389\/fonc.2022.1063305.","journal-title":"Front Oncol"},{"key":"4980_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9029544","author":"X Zhang","year":"2022","unstructured":"Zhang X, Sun M, Jiao Y, Lin B, Yang Q. PHGDH inhibitor CBR-5884 inhibits epithelial ovarian cancer progression via ROS\/Wnt\/\u03b2-catenin pathway and plays a synergistic role with PARP inhibitor olaparib. Oxid Med Cell Longev. 2022. https:\/\/doi.org\/10.1155\/2022\/9029544.","journal-title":"Oxid Med Cell Longev"},{"issue":"Suppl 2","key":"4980_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/1471-0528.17327","volume":"129","author":"X Wu","year":"2022","unstructured":"Wu X, Shen S, Qin J, Fei W, Fan F, Gu J, et al. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer. BJOG. 2022;129(Suppl 2):40\u20139. https:\/\/doi.org\/10.1111\/1471-0528.17327.","journal-title":"BJOG"},{"key":"4980_CR23","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms19071882","volume":"19","author":"SC Nunes","year":"2018","unstructured":"Nunes SC, Serpa J. Glutathione in ovarian cancer: A double-edged sword. Int J Mol Sci. 2018;19:1882. https:\/\/doi.org\/10.3390\/ijms19071882.","journal-title":"Int J Mol Sci"},{"key":"4980_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12967-022-03399-3","volume":"20","author":"X Wang","year":"2022","unstructured":"Wang X, Lu X, Wang P, Chen Q, Xiong L, Tang M, et al. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner. J Transl Med. 2022;20:198. https:\/\/doi.org\/10.1186\/s12967-022-03399-3.","journal-title":"J Transl Med"},{"key":"4980_CR25","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102. https:\/\/doi.org\/10.1093\/nar\/gkx247.","journal-title":"Nucleic Acids Res"},{"key":"4980_CR26","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","volume":"45","author":"B Gy\u0151rffy","year":"2023","unstructured":"Gy\u0151rffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. 2023;45:1889\u201398. https:\/\/doi.org\/10.1007\/s11357-023-00742-4.","journal-title":"GeroScience"},{"key":"4980_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"4980_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151089","volume":"11","author":"W Chowanadisai","year":"2016","unstructured":"Chowanadisai W, Messerli SM, Miller DH, Medina JE, Hamilton JW, Messerli MA, et al. Cisplatin resistant spheroids model clinically relevant survival mechanisms in ovarian tumors. PLoS ONE. 2016;11: e0151089. https:\/\/doi.org\/10.1371\/journal.pone.0151089.","journal-title":"PLoS ONE"},{"key":"4980_CR29","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.7150\/thno.43811","volume":"10","author":"H Sun","year":"2020","unstructured":"Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, et al. Aurora-A\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics. 2020;10:6928\u201345. https:\/\/doi.org\/10.7150\/thno.43811.","journal-title":"Theranostics"},{"key":"4980_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2018.06.009","volume":"28","author":"S Vandekeere","year":"2018","unstructured":"Vandekeere S, Dubois C, Kalucka J, Sullivan MR, Garc\u00eda-Caballero M, Goveia J, et al. Serine synthesis via PHGDH is essential for heme production in endothelial cells. Cell Metab. 2018;28:573-587.e13. https:\/\/doi.org\/10.1016\/j.cmet.2018.06.009.","journal-title":"Cell Metab"},{"key":"4980_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/febs.13211","volume":"282","author":"G Giardina","year":"2015","unstructured":"Giardina G, Brunotti P, Fiascarelli A, Cicalini A, Costa MGS, Buckle AM, et al. How pyridoxal 5\u2032-phosphate differentially regulates human cytosolic and mitochondrial serine hydroxymethyltransferase oligomeric state. FEBS J. 2015;282:1225\u201341. https:\/\/doi.org\/10.1111\/febs.13211.","journal-title":"FEBS J"},{"key":"4980_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.643129","volume":"11","author":"F Bi","year":"2021","unstructured":"Bi F, An Y, Sun T, You Y, Yang Q. PHGDH is upregulated at translational level and implicated in platin-resistant in ovarian cancer cells. Front Oncol. 2021;11: 643129. https:\/\/doi.org\/10.3389\/fonc.2021.643129.","journal-title":"Front Oncol"},{"key":"4980_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25:27\u201342. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.009.","journal-title":"Cell Metab"},{"key":"4980_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jn\/134.3.489","volume":"134","author":"G Wu","year":"2004","unstructured":"Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489\u201392. https:\/\/doi.org\/10.1093\/jn\/134.3.489.","journal-title":"J Nutr"},{"key":"4980_CR35","doi-asserted-by":"publisher","first-page":"12957","DOI":"10.1021\/acs.jmedchem.0c01398","volume":"63","author":"MJ Soth","year":"2020","unstructured":"Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, et al. Discovery of IPN60090, a clinical stage selective glutaminase-1 (GLS-1) inhibitor with excellent pharmacokinetic and physicochemical properties. J Med Chem. 2020;63:12957\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01398.","journal-title":"J Med Chem"},{"key":"4980_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13543776.2023.2173573","volume":"33","author":"D Wang","year":"2023","unstructured":"Wang D, Li X, Gong G, Lu Y, Guo Z, Chen R, et al. An updated patent review of glutaminase inhibitors (2019\u20132022). Expert Opin Ther Pat. 2023;33:17\u201328. https:\/\/doi.org\/10.1080\/13543776.2023.2173573.","journal-title":"Expert Opin Ther Pat"},{"key":"4980_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. Semin Oncol Nurs. 2019;35:151\u20136. https:\/\/doi.org\/10.1016\/j.soncn.2019.02.001.","journal-title":"Semin Oncol Nurs"},{"key":"4980_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41467-019-14083-4","volume":"11","author":"F Tai","year":"2020","unstructured":"Tai F, Gong K, Song K, He Y, Shi J. Enhanced JunD\/RSK3 signalling due to loss of BRD4\/FOXD3\/miR-548d-3p axis determines BET inhibition resistance. Nat Commun. 2020;11:258. https:\/\/doi.org\/10.1038\/s41467-019-14083-4.","journal-title":"Nat Commun"},{"key":"4980_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-019-0900-5","volume":"566","author":"V Sukonina","year":"2019","unstructured":"Sukonina V, Ma H, Zhang W, Bartesaghi S, Subhash S, Heglind M, et al. FOXK1 and FOXK2 regulate aerobic glycolysis. Nature. 2019;566:279\u201383. https:\/\/doi.org\/10.1038\/s41586-019-0900-5.","journal-title":"Nature"},{"key":"4980_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-020-00852-y","volume":"13","author":"S Zheng","year":"2020","unstructured":"Zheng S, Yang L, Zou Y, Liang JY, Liu P, Gao G, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J Hematol Oncol. 2020;13:17. https:\/\/doi.org\/10.1186\/s13045-020-00852-y.","journal-title":"J Hematol Oncol"},{"key":"4980_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3389\/fonc.2020.00545","volume":"10","author":"M Wencong","year":"2020","unstructured":"Wencong M, Jinghan W, Yong Y, Jianyang A, Bin L, Qingbao C, et al. FOXK1 promotes proliferation and metastasis of gallbladder cancer by activating AKT\/mTOR signaling pathway. Front Oncol. 2020;10:545. https:\/\/doi.org\/10.3389\/fonc.2020.00545.","journal-title":"Front Oncol"},{"key":"4980_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biopha.2017.05.087","volume":"92","author":"P Li","year":"2017","unstructured":"Li P, Yu Z, He L, Zhou D, Xie S, Hou H, et al. Knockdown of FOXK1 inhibited the proliferation, migration and invasion in hepatocellular carcinoma cells. Biomed Pharmacother. 2017;92:270\u20136. https:\/\/doi.org\/10.1016\/j.biopha.2017.05.087.","journal-title":"Biomed Pharmacother"},{"key":"4980_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12885-021-09005-x","volume":"22","author":"B Li","year":"2022","unstructured":"Li B, Lou G, Zhang J, Cao N, Yu X. Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p\/FOXK1 axis. BMC Cancer. 2022;22:124. https:\/\/doi.org\/10.1186\/s12885-021-09005-x.","journal-title":"BMC Cancer"},{"key":"4980_CR44","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.2147\/174355","volume":"10","author":"K Xu","year":"2018","unstructured":"Xu K, Liu B, Ma Y, Xu B, Xing X. A novel SWIM domain protein ZSWIM5 inhibits the malignant progression of non-small-cell lung cancer. Cancer Manag Res. 2018;10:3245\u201354. https:\/\/doi.org\/10.2147\/174355.","journal-title":"Cancer Manag Res"},{"key":"4980_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2767-9764.CRC-22-0122","volume":"2","author":"V Clemente","year":"2022","unstructured":"Clemente V, Hoshino A, Shetty M, Nelson A, Erickson BK, Baker R, et al. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. Cancer Res Commun. 2022;2:784\u201394. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0122.","journal-title":"Cancer Res Commun"},{"key":"4980_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s43018-020-00160-x","volume":"2","author":"S Wu","year":"2021","unstructured":"Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat Cancer. 2021;2:189\u2013200. https:\/\/doi.org\/10.1038\/s43018-020-00160-x.","journal-title":"Nat Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-04980-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-04980-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:06:11Z","timestamp":1708517171000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-04980-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4980"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-04980-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The acquisition and use of human specimens were in concordance with the International Ethical Guidelines for Research Involving Human Subjects, as stated in the Helsinki Declaration, and were approved by the Medical Ethics Committee of Guangzhou Women and Children\u2019s Medical Center (2022416B01). All the tissue samples were collected after obtaining signed informed consent from the participants. The use of ovarian cancer tissue microarray (TMA) was approved by the Ethics Committee of Shanghai Outdo Biotech Company (SHYJS-CP-1804010). All experiments involving animals were conducted according to the ethical policies and procedures approved by the Southern Medical University Animal Care and Use Committee (L-2020163).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The authors alone are responsible for the content and writing of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}